Vol 77, No 5 (2009)
REVIEWS
Published online: 2009-08-12
Submitted: 2013-02-22
Antiphospholipid syndrome - an update on diagnosis and treatment
Monika Szturmowicz
Pneumonol Alergol Pol 2009;77(5):460-468.
Vol 77, No 5 (2009)
REVIEWS
Published online: 2009-08-12
Submitted: 2013-02-22
Abstract
Antiphospholipid syndrome (APS) was described by Hughes et al in 1986 and then by Harris et al in 1987. The symptoms of
disease are related to the presence of autoantibodies directed against plasma and serum proteins that form complexes with
phospholipids of cell membranes. The immunologic process involving vascular endothelium, thrombocytes and coagulation
factors is responsible for enhancement of procoagulation mechanisms and as a result - venous and arterial thrombosis.
Actual criteria of recognition of APS were published in 2006 as a result of 11th International Congress on Antiphospholipid
Antibodies which was taking place in 2004 in Sydney. Multiorgan symptoms of disease, criteria of recognition and methods
of treatment were discussed in the present paper.
Abstract
Antiphospholipid syndrome (APS) was described by Hughes et al in 1986 and then by Harris et al in 1987. The symptoms of
disease are related to the presence of autoantibodies directed against plasma and serum proteins that form complexes with
phospholipids of cell membranes. The immunologic process involving vascular endothelium, thrombocytes and coagulation
factors is responsible for enhancement of procoagulation mechanisms and as a result - venous and arterial thrombosis.
Actual criteria of recognition of APS were published in 2006 as a result of 11th International Congress on Antiphospholipid
Antibodies which was taking place in 2004 in Sydney. Multiorgan symptoms of disease, criteria of recognition and methods
of treatment were discussed in the present paper.
Keywords
antiphospholipid syndrome; diagnosis; treatment
Keywords
antiphospholipid syndrome
diagnosis
treatment
Authors
Monika Szturmowicz
About this article